Barclays raised the firm’s price target on AbbVie to $212 from $200 and keeps an Overweight rating on the shares as part of an earnings preview for the biopharmaceutical group. The firm sees a challenging large-cap biopharma setup for Q3.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie sees Q3 adjusted EPS $2.88-$2.92, consensus $2.95
- AbbVie sees FY24 adjusted EPS $10.67-$10.87, consensus $10.87
- Jobs data surprise to upside: Morning Buzz
- AbbVie Lowers Q3 and FY24 Earnings Estimates Amid Higher R&D Charges
- AbbVie’s Allergan Aesthetics announces national availability of JUVEDERM